Clinical and hemodynamic efficacy ofprestarium and its role in the treatment of chronic pulmonary heart

Aim. To assess clinical efficiency and safety of ACE inhibitor prestarium (Servier, France) with specification of its effects on central and pulmonary hemodynamics, hepatic blood flow, indications in patients with chronic pulmonary heart (CPH).
Material and methods. 42 patients with chronic obstructive bronchitis (COB) complicated by CPH
entered the trial. The patients were divided into two groups. Group 1 (n = 26) received standard therapy plus prestarium (2-4 mg/day), group 2 (n = 16) received only standard combined therapy. The
examinees have undergone ultrasonic investigation of the heart and liver in Doppler modes, ECG
monitoring, examination for external respiration function, lipid peroxidation activity, antioxidant blood
defense.
Results. Group 1 demonstrated earlier positive response. It was found that improvement in functional
class of cardiac failure induced by prestarium and less frequent episodes of arrhythmia directly correlated. Positive changes were stated in central and hepatic hemodynamics, systolic pressure in the pulmonary artery lowered more significantly than in the control group.
Conclusion. If COB patients have symptoms of right ventricular failure, they are recommended to take
prestarium in a daily dose 0.004g for 4 weeks to improve intracardiac and hepatic hemodynamics, reduce systolic pressure in the pulmonary artery and number of prognostically unfavourable arrhythmic
episodes.

ACE inhibitors, prestarium, chronic obstructive bronchitis, chronic pulmonary heart, hepatic hemodynamics